Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Instagram Outage Disrupts Thousands of U.S. Users 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SAN ANTONIO, Texas, Aug. 24, 2016 -- bioAffinity Technologies today announced that it has been awarded a U.S. Patent protecting a proprietary kit that contains the CyPath® assay for the early detection of cancer and the prognosis of patient response to cancer therapy.
The U.S. Patent, entitled “5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine (TCPP) and Kit for Use with Detecting Cancer,” relates to the use of the porphyrin-based CyPath® assay for the early detection of dysplastic, pre-cancerous and cancerous cells from tissue samples both in vitro and in situ. CyPath® preferentially binds to cancer cells, giving them a distinctive fluorescence that can be used to detect cancer at an early stage of the disease by an imaging system.
“The newly awarded patent expands our intellectual property estate and provides important protection as we move toward commercialization of our lung cancer assay,” bioAffinity President and CEO Maria Zannes said. “bioAffinity’s current research on the CyPath® diagnostic and our porphyrin-conjugated chemotherapeutic agents for the delivery of drug therapies is reaching beyond product development to provide greater understanding of the fundamental nature of cancer. We are laying the foundation for a game-changing entry into the cancer diagnosis and treatment markets.”
bioAffinity’s patent portfolio includes 42 awarded patents in 21 countries and six patents pending. U.S. Patent 9,417,241 expands on earlier patents for the detection of precancerous, or dysplastic, cells and cancerous cells based on their unique propensity to take up the bioAffinity assay significantly more than healthy cells.
About bioAffinity Technologies
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers. CyPath® Lung, bioAffinity’s initial product, is designed to be the first successful non-invasive, early-stage lung cancer diagnostic on the market.
Contact: Maria Zannes, 505.400.9747
